No profile data available.
TransCode Therapeutics, Inc. (RNAZ) is a healthcare company in the additional cancer treatment drugs industry, based in Boston, United States, with about 12 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$36.27 million. Its market capitalization was $31.49 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers.
TransCode Therapeutics reported $0 in revenue for fiscal year 2025.
$31.49 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Genenta Science S.p.A. (GNTA), Cel-sci Corporation (CVM), NextCure, Inc. (NXTC), Context Therapeutics Inc. (CNTX).